Literature DB >> 11684279

Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process.

D E Epperson1, R Nakamura, Y Saunthararajah, J Melenhorst, A J Barrett.   

Abstract

There is accumulating evidence that the marrow-failure of myelodysplastic syndrome (MDS) is immune-mediated. We studied patients with MDS to look for oligoclonal or clonal expansion in T cells indicative of an autoimmune process. We used a PCR-based technique (spectratyping) to characterize the T cell repertoire in MDS (n=15; 9 RA, 4 RARS, 2 RAEB) and compared results with age-matched healthy donors (n=20) and transfusion-dependent (TD) patients with hemoglobinopathy (n=5). We found a significantly higher number of skewed Vbeta profiles in the MDS patients compared with controls. In peripheral blood T cells, 60/345 Vbeta profiles examined were skewed in MDS patients compared with 3/115 Vbeta profiles in TD controls (P<0.0001), and 58/460 Vbeta profiles in age-matched controls (P=0.05). A study of Jbeta region within the skewed Vbeta profiles revealed preferential usage of Jbeta 2.1 in MDS in contrast with a wide distribution over the entire Jbeta spectrum in controls, consistent with non-random T cell clonal expansion in MDS. These findings provide further evidence that T cell mediated immune processes are a feature of MDS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684279     DOI: 10.1016/s0145-2126(01)00083-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  23 in total

1.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Authors:  Martine E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

Review 2.  Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes.

Authors:  Jingya Wang; Zhijian Xiao
Journal:  Stem Cell Investig       Date:  2014-08-21

Review 3.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 4.  Immune pathophysiology of aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Antonio Risitano; Hoon Kook; Weihua Zeng; Guibin Chen; Neal S Young
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 5.  The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.

Authors:  Adam S Sperling; Christopher J Gibson; Benjamin L Ebert
Journal:  Nat Rev Cancer       Date:  2016-11-11       Impact factor: 60.716

6.  Treatment of myelodysplastic syndrome with cyclosporin A.

Authors:  Shuchang Chen; Bin Jiang; Wanming Da; Ming Gong; Mei Guan
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

Review 7.  Paroxysmal nocturnal hemoglobinuria in children.

Authors:  Marry M van den Heuvel-Eibrink
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

8.  Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome.

Authors:  Marcin W Wlodarski; Lukasz P Gondek; Zachary P Nearman; Magdalena Plasilova; Matt Kalaycio; Eric D Hsi; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2006-04-13       Impact factor: 22.113

9.  Myelodysplasia and Good syndrome. A case report.

Authors:  M Di Renzo; A L Pasqui; L Voltolini; G Gotti; G Pompella; A Auteri
Journal:  Clin Exp Med       Date:  2008-09-13       Impact factor: 3.984

Review 10.  The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders.

Authors:  Ranran Zhang; Mithun Vinod Shah; Thomas P Loughran
Journal:  Hematol Oncol       Date:  2010-09       Impact factor: 5.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.